Screening of a PKC ζ-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis
Screening of a PKC ζ-specific kinase inhibitor PKCzI257.3 which inhibits EGF-induced breast cancer cell chemotaxis
复制标题
DOI：
10.1007/s10637-009-9242-8
复制
发表时间：
2010-06-01
影响因子：
3.4
通讯作者：
Zhang, Ning
中科院分区：
文献类型：
--
作者：
Wu, Jing;Zhang, Baogang;Zhang, Ning
Chemotaxis has recently been implicated in tumor metastasis. Protein Kinase C(PKC)zeta is often over-activated and is a key signal transducer shared by both EGFR- and CXCR4-mediated chemotactic signaling in human breast and lung cancers, as well as CSF-1-induced macrophage migration. In order to develop potential inhibitors targeting PKC zeta for effective blockage of cancer cell chemotaxis and tumor metastasis, the Z'-LYTE (TM) KINASE ASSAY -SER/THR 7 PEPTIDE Kit was used and a compound called PKCzI257.3 was identified with IC50 of 28 A mu M. As a result of treatment, chemotactic migration potency of the human breast cancer cell MDA-MB-231 were impaired, while no significant effect was observed on cell proliferation. Furthermore, EGF-induced cofilin phosphorylation, a critical step of cofilin recycle and actin polymerization, was also dampened, which was relevant to the decreased cell migration. Our results suggest that PKCzI257.3 is a PKC zeta-specific compound inhibitor which blocked cancer cell migration and may serve as a potential therapeutic drug for cancer treatment.
